The American Recovery and Reinvestment Act of 2009

In the time since the preparation of this white paper, $1.1 billion of federal funds have been provided by Congress, through the American Recovery and Reinvestment Act of 2009 (ARRA), to increase national capacity for clinical effectiveness research. AHRQ (Agency for Healthcare Research and Quality) has received $700 million of these funds, of which $400 million will be transferred to the Office of the Director of NIH (National Institutes of Health) to conduct or support comparative effectiveness research (CER) activities.

An additional $400 million will be allocated at the discretion of the Secretary of HHS (Department of Health and Human Services) to:

“…accelerate the development and dissemination of research assessing the comparative effectiveness of health care treatments and strategies, through efforts that: (1) conduct, support, or synthesize research that compares the clinical outcomes, effectiveness, and appropriateness of items, services, and procedures that are used to prevent, diagnose, or treat diseases, disorders, and other health conditions; and (2) encourage the development and use of clinical registries, clinical data networks, and other forms of electronic health data that can be used to generate or obtain outcomes data.”

The recommendations from an Institute of Medicine consensus committee report and from a newly established Federal Coordinating Council on CER within HHS will be considered by the secretary’s office in designating activities to receive funds. Members of the 15-member council will be federal employees or officers appointed by the President, at least half of which will have clinical expertise.

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement